HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types

J Clin Pathol. 2018 Jul;71(7):600-607. doi: 10.1136/jclinpath-2017-204928. Epub 2018 Jan 5.

Abstract

Aims: α-Fetoprotein (AFP)-producing gastric carcinoma (AFPGC) is one of the most aggressive GC subtypes. Frequent expression of human epidermal growth factor receptor 2 (HER2) has previously been reported in hepatoid adenocarcinoma (HAC), a major histological subtype of AFPGC originating from common-type GC (CGC). However, HER2 expression levels in other AFPGC histological subtypes are unknown. In this study, we analysed HER2 expression in GCs with primitive phenotypes in addition to HAC.

Methods: HER2 expression was evaluated in representative complete sections from 16 HACs, 19 GCs with enteroblastic differentiation (GCEDs) and 334 GCs of other histological types as controls. The Ruschoff/Hofmann method was used to score HER2 immunohistochemistry. Samples with a HER2 score of 2+ were further assessed using fluorescence in situ hybridisation. Oncofetal protein (OFP) expression in HAC and GCED was tested via immunohistochemical staining for AFP, glypican 3 and Sal-like protein 4.

Results: Thirty of 35 HAC/GCED cases comprised more than two histological patterns. The HER2 positivity rates of each histological component in the HACs/GCEDs were 25.0% for HAC (n=16), 34.6% for GCED (n=26) and 48.1% for CGC (n=27), which were higher than those of the control group (13.8%). Additionally, the majority of CGC components in HACs/GCEDs were positive for OFP (88.9%).

Conclusions: HER2 is frequently overexpressed not only in HAC but also in GCED and CGC components of HACs/GCEDs, which suggests an association between HER2 and OFP expression. Moreover, our findings suggest that HER2-positive CGC has a higher risk of progression to HAC/GCED than HER2-negative GC.

Keywords: gastric; gastric cancer; gastric pathology; gut pathology.

MeSH terms

  • Adenocarcinoma / chemistry*
  • Adenocarcinoma / classification
  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / analysis*
  • Cell Differentiation* / genetics
  • Female
  • Glypicans / analysis
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization, Fluorescence
  • Male
  • Middle Aged
  • Phenotype
  • Receptor, ErbB-2 / analysis*
  • Receptor, ErbB-2 / genetics
  • Retrospective Studies
  • Stomach Neoplasms / chemistry*
  • Stomach Neoplasms / classification
  • Stomach Neoplasms / genetics
  • Stomach Neoplasms / pathology
  • Transcription Factors / analysis
  • Up-Regulation
  • alpha-Fetoproteins / analysis

Substances

  • AFP protein, human
  • Biomarkers, Tumor
  • GPC3 protein, human
  • Glypicans
  • SALL4 protein, human
  • Transcription Factors
  • alpha-Fetoproteins
  • ERBB2 protein, human
  • Receptor, ErbB-2